Search research articles
Contact Us
Filters
Showing results (1511-1520 of 1,553) with videos related to
Page
of 156
Sort By:
Lancet (London, England)
|
June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Science China. Life Sciences
|
July 14, 2021
Proteomics provides individualized options of precision medicine for patients with gastric cancer
Wenwen Huang, Dongdong Zhan, Yazhuo Li, et al.
JAMA
|
June 28, 2018
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
Jin Li, Shukui Qin, Rui-Hua Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
The New England Journal of Medicine
|
May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Kohei Shitara, Elena Elimova, Tianshu Liu, et al.
Cancer Communications (London, England)
|
October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Jian Li, Ting Deng, Yanhong Gu, et al.
Nature
|
March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A Shah, Kei Muro, et al.
Cancer
|
December 9, 2025
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Jun Zhang, Yanqiao Zhang, Haibo Qiu, et al.
The Journal of Cell Biology
|
November 23, 2021
LUBAC regulates ciliogenesis by promoting CP110 removal from the mother centriole
Xiao-Lin Shen, Jin-Feng Yuan, Xuan-He Qin, et al.
Page
of 156
Search research articles
Search
Showing results (1511-1520 of 1,553) with videos related to
Sort By:
Page
of 156
Lancet (London, England)
|
June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Science China. Life Sciences
|
July 14, 2021
Proteomics provides individualized options of precision medicine for patients with gastric cancer
Wenwen Huang, Dongdong Zhan, Yazhuo Li, et al.
JAMA
|
June 28, 2018
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
Jin Li, Shukui Qin, Rui-Hua Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung-Bae Kim, et al.
The New England Journal of Medicine
|
May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Kohei Shitara, Elena Elimova, Tianshu Liu, et al.
Cancer Communications (London, England)
|
October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Jian Li, Ting Deng, Yanhong Gu, et al.
Nature
|
March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A Shah, Kei Muro, et al.
Cancer
|
December 9, 2025
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Jun Zhang, Yanqiao Zhang, Haibo Qiu, et al.
The Journal of Cell Biology
|
November 23, 2021
LUBAC regulates ciliogenesis by promoting CP110 removal from the mother centriole
Xiao-Lin Shen, Jin-Feng Yuan, Xuan-He Qin, et al.
Page
of 156